The Pharmaletter

InflaRx

A clinical-stage biotech company developing anti-inflammatory therapeutics by targeting the complement system.

Company Overview

Want to Update your Company's Profile?

Latest InflaRx News

The week in pharma: action, reaction and insight – week to January 2, 2026

4 January 2026

InflaRx claims 'signals of efficacy' from analyses of terminated vilobelimab trial

30 December 2025

The week in pharma: action, reaction and insight – week to May 30

1 June 2025

InflaRx ditches vilobelimab Phase III trial in PG

28 May 2025

More InflaRx news >

Copyright © The Pharma Letter 2026

| Headless Content Management with Blaze